Sparsentan is a novel, non-immunosuppressive, single-molecule dual endothelin angiotensin receptor antagonist with high selectivity for ETAR and AT1R.17In the ongoing phase 2 DUET clinical trial in patients with FSGS, administration of sparsentan in the 8-week double-blind period achieved greater proteinuria reduction compared with active control irbesartan.22 The gene discussed is EDNRA; the disease is focal segmental glomerulosclerosis.